Medichem Solutions S.L., a subsidiary of Medichem and a member of Catalonia.health, has announced a strategic collaboration with Breckenridge Pharmaceutical, Inc., a U.S.-based generic pharmaceutical company and subsidiary of Towa International.
Injectable Product Portfolio
The collaboration covers a portfolio of injectable products for hospital and specialty use, including anesthesia, critical care, and emergency medicine. Under the agreement, Medichem Solutions will develop and manufacture selected products at its new state-of-the-art sterile facility in Asturias, Spain, supporting supply to the U.S. market.
By combining Medichem's advanced development and manufacturing expertise with Breckenridge's strong presence in the U.S. hospital channel, the collaboration is designed to support the delivery of high-quality, affordable injectable medicines.
Comprehensive Regulatory and Technical Support
In addition to manufacturing, Medichem will contribute its regulatory and technical expertise, including assisting Breckenridge in the preparation, filing, and prosecution of the ANDA dossier for the U.S. market, ensuring an integrated approach from development through commercialization.
According to Olga Urazova, Chief Commercial Officer of Medichem, "We are very pleased to collaborate with Breckenridge on some of the first products to be manufactured at our new sterile facility. This partnership reflects our shared focus on quality, reliability, and long-term collaboration, and highlights Medichem's ability to support partners across development, manufacturing, and regulatory activities."
Enhanced Capabilities in Sterile Injectables
The collaboration highlights Medichem's strengthened capabilities in sterile injectable development, manufacturing, and global regulatory support – areas of increasing demand as pharmaceutical companies seek flexible, experienced partners capable of advancing products from concept through dossier submission and approval.
Comments